# EDGAR Filing Document

**Accession Number:** 0001849253
**File Stem:** 0000950170-23-005117
**Filing Date:** 2023-2
**Character Count:** 90580
**Document Hash:** 1fc328d976ca563ff5fe0ae3001cf328
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-005117.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0000950170-23-005117

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20221231

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Cost Associated with Exit or Disposal Activities

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RYAN SPECIALTY HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001849253
- **STANDARD INDUSTRIAL CLASSIFICATION:** INSURANCE AGENTS BROKERS & SERVICES [6411]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40645
- **FILM NUMBER:** 23685766

**BUSINESS ADDRESS:**
- **STREET 1:** 180 NORTH STETSON AVENUE, SUITE 4600
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60601
- **BUSINESS PHONE:** (646) 604-3935

**MAIL ADDRESS:**
- **STREET 1:** 180 NORTH STETSON AVENUE, SUITE 4600
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60601

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RYAN SPECIALTY GROUP HOLDINGS, INC.
- **DATE OF NAME CHANGE:** 20210511

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MAVERICK SPECIALTY, INC.
- **DATE OF NAME CHANGE:** 20210304

?xml version="1.0" encoding="ASCII"? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** December 31, 2022<br>

------

RYAN SPECIALTY HOLDINGS, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40645 | 86-2526344 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| Two Prudential Plaza<br>180 N. Stetson Avenue, Suite 4600 |  |  |
| Chicago**,** Illinois |  | 60601 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 312 784-6001<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Class A Common Stock, $0.001 par value | RYAN | The New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On February 28, 2023, Ryan Specialty Holdings, Inc. (the "Company") issued a press release announcing its results of operations for the fourth quarter ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information furnished herewith pursuant to Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this current report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

**Item 2.05 Costs Associated with Exit or Disposal Activities**

On February 22, 2023, the board of directors of the Company approved a two-year restructuring program (the "Program"), which will commence in the first quarter of 2023. The Program is designed to facilitate continued growth, drive innovation, and deliver sustainable productivity improvements over the long term. The Program is expected to generate $35 million of annual cost savings in 2025. The Program includes (i) Operations and Technology Optimization, (ii) Compensation and Benefits, and (iii) Asset Impairment and Other Termination Costs. These actions are expected to be completed by the end of 2024.

The Company currently estimates that the Program will result in cumulative pre-tax charges to its GAAP financial results of approximately $65 million which are expected to be recorded as exit and disposal activities and are broken down as follows:

---

| | |
|:---|:---|
| **Program Activity**  | Charges |
| &nbsp;&nbsp;&nbsp;&nbsp;Operations and Technology Optimization | $45 million |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and Benefits | 15 million |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset Impairment and Other Termination Costs | 5 million |
| **Total** | $**65 million** |

---

The Company currently estimates that approximately 95% of the cumulative pre-tax charges relating to the Program will result in future cash expenditures.

Program charges are recognized as the costs are incurred over time in accordance with GAAP. The Company treats charges related to the Program as special items impacting comparability of results in its earnings disclosures.

The amounts and timing of all estimates are subject to change until finalized. The actual amounts and timing may vary materially based on various factors. See "Cautionary Note Regarding Forward-Looking Statements" below.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibits are furnished herewith:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 99.1 | [<u>Press Release dated February 28, 2023</u>](ryan-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL) |

---

**Cautionary Note Regarding Forward-Looking Statements** 

This report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact included in this report, are forward-looking statements. Forward-looking statements give our current expectations relating to our financial condition, results of operations, plans, objectives, future performance, and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "estimate," "expect," "project," "plan," "intend," "believe," "may," "will," "should," "can have," "likely," and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated costs, expenditures, financial results, our plans, and anticipated cost savings relating to the Program and the amount and timing of delivery of annual cost savings are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, those relating to whether the Company will achieve the associated objectives with its Program, whether the costs and charges associated with restructuring initiatives will exceed current estimates and forecasts, its ability to realize expected savings and benefits in the amounts and at the times anticipated, changes in management's assumptions, its ability to achieve anticipated financial results,

------

risks associated with acquisitions, divestitures, joint ventures and strategic investments, outcomes of legal and regulatory matters, and changes in legislation or regulations. These and other risks, assumptions and uncertainties are described in Item 1A (Risk Factors) of the Company's most recent Annual Report on Form 10-K and in other documents that the Company files or furnishes with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, the Company does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this report, whether as a result of new information, future events, changes in assumptions or otherwise.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **RYAN SPECIALTY HOLDINGS, INC. (Registrant)** |
| Date: | February 28, 2023 | By:  | /s/ Jeremiah R. Bickham |
|  |  |  | Jeremiah R. Bickham<br>Executive Vice President and Chief Financial Officer |

---

------

## Ex-99

![img235980849_0.jpg](img235980849_0.jpg)

 **RYAN SPECIALTY REPORTS FOURTH QUARTER 2022 RESULTS**

- Total Revenue grew 14.9% year-over-year to $435.0 million -

- Organic Revenue Growth Rate of 10.3% year-over-year -

- Net Income of $45.8 million, or $0.14 per diluted share -

- Adjusted EBITDAC grew 5.8% year-over-year to $127.3 million -

- Adjusted Net Income declined 4.1% year over year to $73.8 million, or $0.27 per diluted share -

- Initiates 2023 outlook for Organic Revenue Growth Rate and Adjusted EBITDAC Margin -

**FEBRUARY 28, 2023 \| CHICAGO, IL —** Ryan Specialty Holdings, Inc. (NYSE: RYAN) ("Ryan Specialty" or the "Company"), a leading international specialty insurance firm, today announced results for the fourth quarter ended December 31, 2022.

**Fourth Quarter 2022 Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;•Revenue grew 14.9% year-over-year to $435.0 million, compared to $378.5 million in the prior-year period

&nbsp;&nbsp;&nbsp;&nbsp;•Organic Revenue Growth Rate\* was 10.3% for the quarter, compared to 15.4% in the prior-year period

&nbsp;&nbsp;&nbsp;&nbsp;•Net Income grew 54.6% year-over-year to $45.8 million, compared to $29.6 million in the prior-year period. Diluted Earnings per Share was $0.14

&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDAC\* increased 5.8% to $127.3 million, compared to $120.3 million in the prior-year period

&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDAC Margin\* of 29.3%, compared to 31.8% in the prior-year period

&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted Net Income\* decreased 4.1% to $73.8 million, compared to $77.0 million in the prior-year period

&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted Diluted Earnings per Share\* decreased 6.9% to $0.27, compared to $0.29 in the prior-year period

**Full Year 2022 Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;•Total Revenue grew 20.4% year-over-year to $1.7 billion, compared to $1.4 billion in the prior year

&nbsp;&nbsp;&nbsp;&nbsp;•Organic Revenue Growth Rate\* was 16.4%, compared to 22.4% for the prior year

&nbsp;&nbsp;&nbsp;&nbsp;•Net Income grew 188.3% year over year to $163.3 million, compared to $56.6 million in the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDAC\* increased 12.4% to $517.4 million, compared to $460.2 million in the prior year

&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDAC Margin\* of 30.0%, compared to 32.1% for the prior year

&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted Net Income\* increased 7.5% to $312.0 million, compared to $290.1 million in the prior year

&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted Diluted Earnings per Share\* increased 6.5% to $1.15, compared to $1.08 for the prior year

------

"The Ryan Specialty team ended 2022 on a strong note, as another quarter of double-digit organic growth enabled us to generate 16% organic revenue growth for the full year, an outstanding accomplishment considering the progressively challenging macro environment throughout the year," said Patrick G. Ryan, Founder, Chairman and Chief Executive Officer of Ryan Specialty. "This performance is continued validation of our differentiated business model and the strong execution from our world-class teammates throughout the year on behalf of our clients. As we look ahead to 2023, we see clear opportunities to invest in our business and optimize our operations to create additional efficiencies and enhance our platform in order to capitalize on growth opportunities while accelerating margins in the mid to long term. We remain well positioned with our strong balance sheet and E&S focus to continue expanding our market share, generating profitable growth and delivering long-term value for our investors."

**Summary of Fourth Quarter 2022 Results**

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Change** |
| (in thousands, except percentages and per share data) | **2022** | **2021** | **%** |
| **GAAP financial measures** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue | $435015 | $378535 | 14.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and benefits | 270542 | 253793 | 6.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 57120 | 41971 | 36.1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 355766 | 323286 | 10.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income | 79249 | 55249 | 43.4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | 45782 | 29616 | 54.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to Ryan Specialty Holdings, Inc. | 17895 | 10051 | 78.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenue growth rate (1) | 14.9% | 15.8% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and benefits expense ratio (2) | 62.2% | 67.0% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense ratio (3) | 13.1% | 11.1% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income margin | 10.5% | 7.8% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings (loss) per share (4) | $0.16 | $0.10 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings (loss) per share (4) | $0.14 | $0.09 |  |
| **Non-GAAP financial measures\*** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic revenue growth rate | 10.3% | 15.4% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted compensation and benefits expense | $252571 | $221111 | 14% |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted compensation and benefits expense ratio | 58.1% | 58.4% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted general and administrative expense | $55182 | $37107 | 48.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted general and administrative expense ratio | 12.7% | 9.8% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDAC | $127262 | $120317 | 5.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDAC margin | 29.3% | 31.8% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted net income | $73833 | $76983 | (4.1)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted net income margin | 17.0% | 20.3% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted diluted earnings per share | $0.27 | $0.29 |  |

---

\* For a definition and a reconciliation of Organic revenue growth rate, Adjusted compensation and benefits expense, Adjusted compensation and benefits ratio, Adjusted general and administrative expense, Adjusted general and administrative expense ratio, Adjusted EBITDAC, Adjusted EBITDAC margin, Adjusted net income, Adjusted net income margin, and Adjusted diluted earnings per share to the most directly comparable GAAP measure, see "Non-GAAP Financial Measures and Key Performance Indicators" below.

(1)Total revenue growth rate is defined as December 31, 2022 revenue of $435.0 million less December 31, 2021 revenue of $378.5 million is a $56.5 million period-over-period change. The change, $56.5 million, divided by the December 31, 2021 revenue of $378.5 million is a total revenue change of 14.9%. December 31, 2021 revenue of $378.5 million less December 31, 2020 revenue of $326.9 million is a $51.6 million period-over-period change. The change, $51.6 million, divided by the December 31, 2020 revenue of $326.9 million is a total revenue change of 15.8%

(2)Compensation and benefits expense ratio is defined as Compensation and benefits divided by Total revenue.

(3)General and administrative expense ratio is defined as General and administrative expense divided by Total revenue.

(4)See "Note 13, Earnings (Loss) Per Share" of the annual consolidated financial statements.

------

**Fourth Quarter 2022 Review\***

Total revenue for the fourth quarter of 2022 was $435.0 million, an increase of 14.9% compared to $378.5 million in the prior-year period. This increase was primarily due to continued solid Organic revenue growth of 10.3%, driven by new client wins and expanded relationships with existing clients, coupled with continued expansion of the E&S market, revenue from acquisitions completed in the fourth quarter of 2021 and increased Fiduciary investment income.

Total operating expenses for the fourth quarter of 2022 were $355.8 million, a 10.0% increase compared to the prior-year period. This was primarily due to an increase in Compensation and benefits expense, which is heavily correlated to revenue growth, offset by a decline in Acquisition related long-term incentives as the final payments related to the All Risks LTIP plan were made in Q3 2022 and IPO related compensation as time passes and awards vest. General and administrative expense also increased compared to the prior-year period to accommodate revenue growth, including continued normalization of business travel and client entertainment.

Net income for the fourth quarter of 2022 increased 54.6% to $45.8 million, compared to $29.6 million in the prior-year period. The increase was mainly due to strong year-over-year revenue growth, lower IPO related charges, and partially offset by higher Interest expense, net. Diluted earnings per share for the fourth quarter of 2022 was $0.14, compared to $0.09 in the prior-year period.

Adjusted EBITDAC of $127.3 million grew 5.8% from $120.3 million in the prior-year period. Adjusted EBITDAC margin for the quarter was 29.3%, compared to 31.8% in the prior-year period. The increase in Adjusted EBITDAC was driven primarily by solid revenue growth and higher Fiduciary investment income, partially offset by increased Adjusted compensation and benefits expense, as well as higher Adjusted general and administrative expense.

Adjusted net income for the fourth quarter of 2022 decreased 4.1% to $73.8 million, compared to $77.0 million in the prior-year period. Adjusted net income margin was 17.0%, compared to 20.3% in the prior-year period. Adjusted diluted earnings per share for the fourth quarter of 2022 decreased 6.9% to $0.27, compared to $0.29 in the prior-year period.

\* For the definition of each of the non-GAAP measures referred to above as well as a reconciliation of such non-GAAP measures to their most directly comparable GAAP measures, see "Non-GAAP Financial Measures and Key Performance Indicators" below.

**Fourth Quarter 2022 Revenue by Specialty**

Growth in Net commissions and fees in all specialties was primarily driven by solid organic growth.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Period over Period** | **Period over Period** |
| (in thousands, except percentages) | **2022** | **% of<br>total** | **2021** | **% of<br>total** | **Change** | **Change** |
| Wholesale Brokerage | $287968 | 67.4% | $255750 | 67.6% | $32218 | 12.6% |
| Binding Authority | 52697 | 12.3 | 48186 | 12.7 | 4511 | 9.4 |
| Underwriting Management | 86737 | 20.3 | 74443 | 19.7 | 12294 | 16.5 |
| **Total Net commissions and fees** | $**427402** |  | $**378379** |  | $**49023** | **13.0%** |

---

**Liquidity and Financial Condition**

As of December 31, 2022, the Company had Cash and cash equivalents of $992.7 million and outstanding debt principal of $2.0 billion.

------

**ACCELERATE 2025** 

Today we are announcing ACCELERATE 2025, a two-year restructuring program, effective in the first quarter, that will enable continued growth, drive innovation, and deliver sustainable productivity improvements over the long term. The program will result in approximately $65 million of cumulative one-time charges through 2024 and we expect the program to generate annual savings of approximately $35 million in 2025.

**Full Year 2023 Outlook\***

The Company is initiating its full year 2023 outlook for both Organic Revenue Growth Rate and Adjusted EBITDAC Margin as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Organic Revenue Growth Rate guidance for full year 2023 to be between 10.0% – 13.0%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDAC Margin guidance for full year 2023 to be between 29.0% – 30.0%

\* For a definition of Organic revenue growth rate and Adjusted EBITDAC margin as well as an explanation of the Company's inability to provide reconciliations of these forward-looking non-GAAP measures, see "Non-GAAP Financial Measures and Key Performance Indicators" below.

**Conference Call Information**

Ryan Specialty will host a conference call today at 5:00 PM ET to discuss these results. A live audio webcast of the conference call will be available on the Company's website at ryanspecialty.com in its Investors section.

The dial-in number for the conference call is (877) 451-6152 (toll-free) or (201) 389-0879 (international). Please dial the number 10 minutes prior to the scheduled start time.

A webcast replay of the call will be available on the Company's website at ryanspecialty.com in its Investors section for one year following the call.

**About Ryan Specialty**

Founded in 2010, Ryan Specialty (NYSE: RYAN) is a service provider of specialty products and solutions for insurance brokers, agents and carriers. Ryan Specialty provides distribution, underwriting, product development, administration and risk management services by acting as a wholesale broker and a managing underwriter with delegated authority from insurance carriers. Our mission is to provide industry-leading innovative specialty insurance solutions for insurance brokers, agents and carriers. Learn more at ryanspecialty.com.

**Forward-Looking Statements**

All statements in this release and in the corresponding earnings call that are not historical are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve substantial risks and uncertainties. For example, all statements the Company makes relating to its estimated and projected costs, expenditures, cash flows, growth rates and financial results or its plans and objectives for future operations, growth initiatives, or strategies and the statements under the caption "Full Year 2023 Outlook" and "Accelerate 2025" are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "plan," "intend," "believe," "may," "will," "should," "can have," "likely" and variations of such words and similar expressions are intended to identify such forward-looking statements. All forward-looking statements are subject to risks and uncertainties, known and unknown, that may cause actual results to differ materially from those that the Company expected. Specific factors that could cause such a difference include, but are not limited to, those disclosed previously in the Company's filings with the Securities and Exchange Commission ("SEC") that include, but are not limited to: the Company's potential failure to develop a succession plan for the senior management team, including

------

Patrick G. Ryan; the Company's failure to recruit and retain revenue producers; the cyclicality of, and the economic conditions in, the markets in which the Company operates; conditions that result in reduced insurer capacity; the potential loss of the Company's relationships with insurance carriers or its clients, becoming dependent upon a limited number of insurance carriers or clients or the failure to develop new insurance carrier and client relationships; significant competitive pressures in each of the Company's businesses; decreases in the premiums or commission rates set by insurers, or actions by insurers seeking repayment of commissions; decreases in the amounts of supplemental or contingent commissions the Company receives; the Company's inability to collect its receivables; the potential that the Company's underwriting models contain errors or are otherwise ineffective; any damage to the Company's reputation; decreases in current market share as a result of disintermediation within the insurance industry; impairment of goodwill; the inability to maintain rapid growth or to generate sufficient revenue to achieve and maintain profitability; the impact if the Company's MGU programs are terminated or changed; the risks associated with the evaluation of potential acquisitions and the integration of acquired businesses as well as introduction of new products, lines of business and markets; the occurrence of natural or man-made disasters; being subject to E&O claims as well as other contingencies and legal proceedings; the impact on the Company's operations and financial condition from the effects of the current COVID-19 pandemic; the impact of breaches in security that cause significant system or network disruptions; not being able to generate sufficient cash flow to service all of the Company's indebtedness and being forced to take other actions to satisfy its obligations under such indebtedness; and the impact of being unable to refinance the Company's indebtedness.

For more detail on the risk factors that may affect the Company's results, see the section entitled ''Risk Factors'' in our most recent annual report on Form 10-K filed with the SEC, and in other documents filed with, or furnished to, the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Given these factors, as well as other variables that may affect the Company's operating results, you are cautioned not to place undue reliance on these forward-looking statements, not to assume that past financial performance will be a reliable indicator of future performance, and not to use historical trends to anticipate results or trends in future periods. The forward-looking statements included in this press release and on the related earnings call relate only to events as of the date hereof. The Company does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

**Non-GAAP Financial Measures and Key Performance Indicators**

In assessing the performance of the Company's business, non-GAAP financial measures are used that are derived from the Company's consolidated financial information, but which are not presented in the Company's consolidated financial statements prepared in accordance with GAAP. The Company considers these non-GAAP financial measures to be useful metrics for management and investors to facilitate operating performance comparisons from period to period by excluding potential differences caused by variations in capital structures, tax positions, depreciation, amortization and certain other items that the Company believes are not representative of its core business. The Company uses the following non-GAAP measures for business planning purposes, in measuring performance relative to that of its competitors, to help investors to understand the nature of the Company's growth, and to enable investors to evaluate the run-rate performance of the Company. Non-GAAP financial measures should be viewed as supplementing, and not as an alternative or substitute for, the consolidated financial statements prepared and presented in accordance with GAAP. The footnotes to the reconciliation tables below should be read in conjunction with the audited consolidated financial statements in our Annual Report on form 10-K filed with the SEC. Industry peers may provide similar supplemental information but may not define similarly-named metrics in the same way and may not make identical adjustments.

**Organic revenue growth rate:** Organic revenue growth rate is defined as the percentage change in Total revenue, as compared to the prior-year period, adjusted for revenue attributable to acquisitions during their first 12 months

------

of the Company's ownership, and other adjustments such as contingent commissions, Fiduciary investment income, and the impact of changes in foreign exchange rates. The most directly comparable GAAP financial metric is Total revenue growth rate.

**Adjusted compensation and benefits expense:** Adjusted compensation and benefits expense is defined as Compensation and benefits expense adjusted to reflect items such as (i) equity-based compensation, (ii) acquisition and restructuring related compensation expenses, and (iii) other exceptional or non-recurring compensation expenses, as applicable. The most directly comparable GAAP financial metric is Compensation and benefits expense.

**Adjusted general and administrative expense:** Adjusted general and administrative expense is defined as General and administrative expense adjusted to reflect items such as (i) acquisition and restructuring related general and administrative expenses, and (ii) other exceptional or non-recurring general and administrative expenses, as applicable. The most directly comparable GAAP financial metric is General and administrative expense.

**Adjusted compensation and benefits expense ratio:** Adjusted compensation and benefits expense ratio is defined as the Adjusted compensation and benefits expense as a percentage of Total revenue. The most directly comparable GAAP financial metric is Compensation and benefits expense ratio.

**Adjusted general and administrative expense ratio:** Adjusted general and administrative expense ratio is defined as the Adjusted general and administrative expense as a percentage of Total revenue. The most directly comparable GAAP financial metric is General and administrative expense ratio.

**Adjusted EBITDAC:** Adjusted EBITDAC is defined as Net income before Interest expense, net, Income tax expense, Depreciation, Amortization, and Change in contingent consideration, adjusted to reflect items such as (i) equity-based compensation, (ii) acquisition-related expenses, and (iii) other exceptional or non-recurring items, as applicable. The most directly comparable GAAP financial metric is Net income.

**Adjusted EBITDAC margin**: Adjusted EBITDAC margin is defined as Adjusted EBITDAC as a percentage of Total revenue. The most directly comparable GAAP financial metric is Net income margin.

**Adjusted net income**: Adjusted net income is defined as tax-effected earnings before amortization and certain items of income and expense, gains and losses, equity-based compensation, acquisition related long-term incentive compensation, acquisition-related expenses, costs associated with our Initial Public Offering (the "IPO") and certain exceptional or non-recurring items. The Company will be subject to United States federal income taxes, in addition to state, local, and foreign taxes, with respect to its allocable share of any net taxable income of Ryan Specialty, LLC (together with its parent New Ryan Specialty, LLC and their subsidiaries, the "LLC"). For comparability purposes, this calculation incorporates the impact of federal and state statutory tax rates on 100% of the Company's adjusted pre-tax income as if the Company owned 100% of Ryan Specialty, LLC. The most directly comparable GAAP financial metric is Net income.

**Adjusted net income margin**: Adjusted net income margin is defined as Adjusted net income as a percentage of Total revenue. The most directly comparable GAAP financial metric is Net income margin.

**Adjusted diluted earnings per share:** Adjusted diluted earnings per share is defined as Adjusted net income divided by diluted shares outstanding after adjusting for the effect of the exchange of 100% of the outstanding non-voting common interest units of New Ryan Specialty, LLC ("LLC Common Units"), together with the shares of Class B common stock, into shares of Class A common stock and the effect of unvested equity awards. The most directly comparable GAAP financial metric is Diluted earnings (loss) per share.

The reconciliation of the above non-GAAP measures to their most directly comparable GAAP financial measure is set forth in the reconciliation table accompanying this release.

------

With respect to the Organic revenue growth rate and Adjusted EBITDAC margin outlook presented in the "Full Year 2023 Outlook" section of this press release, the Company is unable to provide a comparable outlook for, or a reconciliation to, Total revenue growth rate or Net income margin because it cannot provide a meaningful or accurate calculation or estimation of certain reconciling items without unreasonable effort. Its inability to do so is due to the inherent difficulty in forecasting the timing of items that have not yet occurred and quantifying certain amounts that are necessary for such reconciliation, including variations in effective tax rate, expenses to be incurred for acquisition activities and other one-time or exceptional items.

**Contacts:**

---

| | |
|:---|:---|
| **Investor Relations**<br>Noah Angeletti<br>SVP, Head of Investor Relations & Treasurer<br>Ryan Specialty<br>IR@ryanspecialty.com<br>Phone: (312) 784-6152 | **Media Relations**<br>Alice Phillips Topping<br>SVP, Chief Marketing & Communications Officer<br>Ryan Specialty<br>Alice.Topping@ryansg.com<br> Phone: (312) 635-5976 |

---

------

**Consolidated Statements of Income (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| **REVENUE** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net commissions and fees | $427402 | $378379 | $1711861 | $1432179 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fiduciary investment income | 7613 | 156 | 13332 | 592 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenue** | $**435015** | $**378535** | $**1725193** | $**1432771** |
| **EXPENSES** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and benefits | 270542 | 253793 | 1128981 | 991618 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 57120 | 41971 | 196971 | 138955 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 25038 | 25782 | 103601 | 107877 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 1787 | 1205 | 5690 | 4806 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in contingent consideration | 1279 | 535 | 442 | 2891 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** | $**355766** | $**323286** | $**1435685** | $**1246147** |
| **OPERATING INCOME** | $**79249** | $**55249** | $**289508** | $**186624** |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 29367 | 19130 | 104829 | 79354 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss from equity method investment in related party |  | 1369 | 414 | 759 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-operating (income) loss | (1759) | (600) | 5073 | 44947 |
| **INCOME BEFORE INCOME TAXES** | $**51641** | $**35350** | $**179192** | $**61564** |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 5859 | 5734 | 15935 | 4932 |
| **NET INCOME** | $**45782** | $**29616** | $**163257** | $**56632** |
| **GAAP financial measures** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenue | $435015 | $378535 | $1725193 | $1432771 |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and benefits | 270542 | 253793 | 1128981 | 991618 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 57120 | 41971 | 196971 | 138955 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | 45782 | 29616 | 163257 | 56632 |
| &nbsp;&nbsp;&nbsp;&nbsp;Compensation and benefits expense ratio | 62.2% | 67.0% | 65.4% | 69.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense ratio | 13.1% | 11.1% | 11.4% | 9.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income margin | 10.5% | 7.8% | 9.5% | 4.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;Earnings per share | $0.16 | $0.10 | $0.57 | $(0.07) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings per share | $0.14 | $0.09 | $0.52 | $(0.07) |

---

**Non-GAAP Financial Measures (Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| (in thousands, except percentages and per share data) | **2022** | **2021** | **2022** | **2021** |
| **Non-GAAP financial measures\*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Organic revenue growth rate | 10.3% | 15.4% | 16.4% | 22.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted compensation and benefits expense | $252571 | $221111 | $1021823 | $846563 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted compensation and benefits expense ratio | 58.1% | 58.4% | 59.2% | 59.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted general and administrative expense | $55182 | $37107 | $185956 | $125977 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted general and administrative expense ratio | 12.7% | 9.8% | 10.8% | 8.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDAC | $127262 | $120317 | $517414 | $460231 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDAC margin | 29.3% | 31.8% | 30.0% | 32.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted net income | $73833 | $76983 | $311991 | $290117 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted net income margin | 17.0% | 20.3% | 18.1% | 20.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted diluted earnings per share | $0.27 | $0.29 | $1.15 | $1.08 |

---

------

**Consolidated Balance Sheets (Unaudited)**

---

| | | |
|:---|:---|:---|
| (in thousands, except share and per share data) | **December 31, 2022** | **December 31, 2021** |
| **ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**CURRENT ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $992723 | $386962 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commissions and fees receivable – net | 231423 | 210252 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fiduciary cash and receivables | 2611647 | 2390185 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid incentives – net | 8584 | 7726 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 49690 | 15882 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current assets** | $**3894067** | $**3011007** |
| &nbsp;&nbsp;&nbsp;&nbsp;**NON-CURRENT ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 1314984 | 1309267 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other intangible assets | 486444 | 573930 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid incentives – net | 20792 | 25382 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity method investment in related party | 38514 | 45417 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment – net | 31271 | 15290 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease right-of-use assets | 143870 | 84874 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax assets | 396814 | 382753 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-current assets | 56987 | 10788 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total non-current assets** | $**2489676** | $**2447701** |
| **TOTAL ASSETS** | $**6383743** | $**5458708** |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**CURRENT LIABILITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 119022 | 99403 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | 350369 | 386301 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 22744 | 18783 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term debt and current portion of long-term debt | 30587 | 23469 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fiduciary liabilities | 2611647 | 2390185 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current liabilities** | $**3134369** | $**2918141** |
| &nbsp;&nbsp;&nbsp;&nbsp;**NON-CURRENT LIABILITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | 10048 | 4371 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 151944 | 74386 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt | 1951900 | 1566627 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax liabilities | 562 | 631 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax Receivable Agreement liabilities | 295347 | 272100 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-current liabilities | 21761 | 27675 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total non-current liabilities** | $**2431562** | $**1945790** |
| **TOTAL LIABILITIES** | $**5565931** | $**4863931** |
| **STOCKHOLDERS' EQUITY** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Class A common stock ($0.001 par value; 1,000,000,000 shares authorized, 112,437,825 and 109,894,548 shares issued and outstanding at December 31, 2022 and 2021, respectively) | 112 | 110 |
| &nbsp;&nbsp;&nbsp;&nbsp;Class B common stock ($0.001 par value; 1,000,000,000 shares authorized, 147,214,275 and 149,162,107 shares issued and outstanding at December 31, 2022 and 2021, respectively) | 147 | 149 |
| &nbsp;&nbsp;&nbsp;&nbsp;Class X common stock ($0.001 par value; 10,000,000 shares authorized, 640,784 shares issued and 0 outstanding at December 31, 2022 and 2021) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock ($0.001 par value; 500,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2022 and 2021) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 418123 | 348865 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings (accumulated deficit) | 53988 | (7064) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | 6035 | 1714 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total stockholders' equity attributable to Ryan Specialty Holdings, Inc.** | $**478405** | $**343774** |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-controlling interests | 339407 | 251003 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total stockholders' equity** | $**817812** | $**594777** |
| **TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY** | $**6383743** | $**5458708** |

---

------

**Consolidated Statements of Cash Flows (Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
| (in thousands) | **2022** | **2021** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | $163257 | $56632 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to cash flows provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) from equity method investment in related party | 414 | 759 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization | 103601 | 107877 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 5690 | 4806 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid and deferred compensation expense | 28831 | 46470 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash equity-based compensation | 77480 | 67534 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred debt issuance costs | 12054 | 11372 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of interest rate cap premium | 4636 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income tax expense (benefit) | 8986 | (1154) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on extinguishment of existing debt |  | 8634 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on Tax Receivable Agreement | 5553 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change (net of acquisitions) in: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commissions and fees receivable – net | (20370) | (29657) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest liability | 7776 | 760 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets and accrued liabilities | (63659) | 78728 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-current assets and accrued liabilities | 1265 | (79268) |
| **Total cash flows provided by operating activities** | $**335514** | $**273493** |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Business combinations - net of cash acquired and cash held in a fiduciary capacity |  | (108883) |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset acquisitions | (7714) | (343158) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid incentives issued – net of repayments | 337 | 3885 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity method investment in related party |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | (15043) | (9781) |
| **Total cash flows used for investing activities** | $**(22420)** | $**(457937)** |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Contributions of members' and mezzanine equity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Allocation of contribution to Redeemable Preferred Units embedded derivative |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from senior secured notes | 394000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of interest rate cap premium | (25500) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate cap receipts | 2174 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of term debt | (16500) | (16500) |
| &nbsp;&nbsp;&nbsp;&nbsp;Borrowing of term debt |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt issuance costs paid | (2369) | (2431) |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance lease and other costs paid | (36) | (129) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of contingent consideration | (6241) | (4495) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of remaining interest in Ryan Re |  | (48368) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of preferred equity |  | (78256) |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax distributions to LLC unitholders | (39883) | (47096) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity repurchases from pre-IPO unitholders |  | (3880) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of Class A common stock in the IPO |  | (183616) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of pre-IPO LLC Units and payment of Alternative TRA Payments |  | (780352) |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of Class A common stock in the IPO, net of offering costs paid |  | 1448097 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of unsecured promissory notes |  | (1108) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of subordinated notes |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Borrowings on revolving credit facilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments on revolving credit facilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Receipt of taxes related to net share settlement of equity awards | 7168 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes paid related to net share settlement of equity awards | (7168) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payment of Tax Receivable Agreement liabilities | (8309) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net change in fiduciary liabilities | 17420 | 147418 |
| **Total cash flows provided by financing activities** | $**314756** | $**429284** |
| **Effect of changes in foreign exchange rates on cash, cash equivalents, and cash held in a fiduciary capacity** | **(126)** | **(883)** |
| **NET CHANGE IN CASH, CASH EQUIVALENTS, AND CASH HELD IN A FIDUCIARY CAPACITY** | $**627724** | $**243957** |
| **CASH, CASH EQUIVALENTS, AND CASH HELD IN A FIDUCIARY CAPACITY—Beginning balance** | **1139661** | **895704** |
| **CASH, CASH EQUIVALENTS, AND CASH HELD IN A FIDUCIARY CAPACITY—Ending balance** | $**1767385** | $**1139661** |
| **Reconciliation of cash, cash equivalents, and cash held in a fiduciary capacity** |  |  |
| Cash and cash equivalents | 992723 | 386962 |
| Cash held in a fiduciary capacity | 774662 | 752699 |
| **Total cash, cash equivalents, and cash held in a fiduciary capacity** | $**1767385** | $**1139661** |

---

------

**Net Commissions and Fees**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Period over Period** | **Period over Period** |
| (in thousands, except percentages) | **2022** | **% of<br>total** | **2021** | **% of<br>total** | **Change** | **Change** |
| Wholesale Brokerage | $287968 | 67.4% | $255750 | 67.6% | $32218 | 12.6% |
| Binding Authority | 52697 | 12.3 | 48186 | 12.7 | 4511 | 9.4 |
| Underwriting Management | 86737 | 20.3 | 74443 | 19.7 | 12294 | 16.5 |
| **Total Net commissions and fees** | $**427402** |  | $**378379** |  | $**49023** | **13.0%** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Period over Period** | **Period over Period** |
| (in thousands, except percentages) | **2022** | **% of<br>total** | **2021** | **% of<br>total** | **Change** | **Change** |
| Wholesale Brokerage | $1129241 | 66.0% | $931979 | 65.1% | $197262 | 21.2% |
| Binding Authority | 231048 | 13.5 | 209622 | 14.6 | 21426 | 10.2 |
| Underwriting Management | 351572 | 20.5 | 290578 | 20.3 | 60994 | 21.0 |
| **Total Net commissions and fees** | $**1711861** |  | $**1432179** |  | $**279682** | **19.5%** |

---

------

**Reconciliation of Organic Revenue Growth Rate to Total Revenue Growth Rate**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **December 31,** | **December 31,** |
|  | **2022** | **2021** |
| **Total Revenue Growth Rate (GAAP) (1)** | **14.9%** | **15.8%** |
| Less: Mergers and Acquisitions (2) | (2.2) | (0.6) |
| Change in Other (3) | (2.4) | 0.2 |
| **Organic Revenue Growth Rate (Non-GAAP)** | **10.3%** | **15.4%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)December 31, 2022 revenue of $435.0 million less December 31, 2021 revenue of $378.5 million is a $56.5 million period-over-period change. The change, $56.5 million, divided by the December 31, 2021 revenue of $378.5 million is a total revenue change of 14.9%. December 31, 2021 revenue of $378.5 million less December 31, 2020 revenue of $326.9 million is a $51.6 million period-over-period change. The change, $51.6 million, divided by the December 31, 2020 revenue of $326.9 million is a total revenue change of 15.8%.

&nbsp;&nbsp;&nbsp;&nbsp;(2)The acquisitions adjustment excludes net commission and fees revenue generated during the first 12 months following an acquisition. The total adjustment for the three months ended December 31, 2022 and 2021 was $8.5 million and $1.9 million, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;(3)The other adjustments exclude the period-over-period change in contingent commissions, fiduciary investment income, and foreign exchange rates. The total adjustment for the three months ended December 31, 2022 and 2021 was $8.9 million and $0.6 million, respectively.

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2022** | **2021** |
| **Total Revenue Growth Rate (GAAP) (1)** | **20.4%** | **40.7%** |
| Less: Mergers and Acquisitions (2) | (2.8) | (18.3) |
| Change in Other (3) | (1.2) | 0.0 |
| **Organic Revenue Growth Rate (Non-GAAP)** | **16.4%** | **22.4%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)December 31, 2022 revenue of $1,725.2 million less December 31, 2021 revenue of $1,432.8 million is a $292.4 million year-over-year change. The change, $292.4 million, divided by the December 31, 2021 revenue of $1,432.8 million is a total revenue change of 20.4%. December 31, 2021 revenue of $1,432.8 million less December 31, 2020 revenue of $1,018.3 million is a $414,497 year-over-year change. The change, $414,497, divided by the December 31, 2020 revenue of $1,018.3 million is a total revenue change of 40.7%. See "Comparison of the Year Ended December 31, 2022 and 2021" for further details.

&nbsp;&nbsp;&nbsp;&nbsp;(2)The mergers and acquisitions adjustment excludes net commission and fees revenue generated during the first 12 months following an acquisition. The total adjustment for the years ended December 31, 2022 and 2021 was $40.0 million and $186.4 million, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;(3)The other adjustments exclude the year-over-year change in contingent commissions, fiduciary investment income, and foreign exchange rates. The total adjustment for the years ended December 31, 2022 and 2021 was $16.0 million and $0.6 million, respectively.

------

**Reconciliation of Adjusted Compensation and Benefits Expense to Compensation and Benefits Expense**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **December 31,** | **December 31,** |
| (in thousands, except percentages) | **2022** | **2021** |
| **Total Revenue** | $**435015** | $**378535** |
| **Compensation and Benefits Expense** | $**270542** | $**253793** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition related long-term incentive compensation | 88 | (9568) |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related expense |  | (688) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization and expense related to discontinued prepaid<br> incentives | (1663) | (1768) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | (5380) | (2380) |
| &nbsp;&nbsp;&nbsp;&nbsp;IPO related expenses | (11016) | (18278) |
| **Adjusted Compensation and Benefits Expense (1)** | $**252571** | $**221111** |
| **Compensation and Benefits Expense Ratio** | **62.2%** | **67.0%** |
| **Adjusted Compensation and Benefits Expense Ratio** | **58.1%** | **58.4%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)Adjustments made to Compensation and benefits expense are described in the footnotes of the reconciliation of Adjusted EBITDAC to Net income in "Reconciliation of Adjusted EBITDAC to Net Income."

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
| (in thousands, except percentages) | **2022** | **2021** |
| **Total Revenue** | $**1725193** | $**1432771** |
| **Compensation and Benefits Expense** | $**1128981** | $**991618** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expense | (122) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition related long-term incentive compensation | (22093) | (38405) |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related expense | (724) | (9934) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization and expense related to discontinued prepaid<br> incentives | (6738) | (7209) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | (23390) | (13639) |
| &nbsp;&nbsp;&nbsp;&nbsp;IPO related expenses | (54091) | (75868) |
| **Adjusted Compensation and Benefits Expense (1)** | $**1021823** | $**846563** |
| **Compensation and Benefits Expense Ratio** | **65.4%** | **69.2%** |
| **Adjusted Compensation and Benefits Expense Ratio** | **59.2%** | **59.1%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)Adjustments made to Compensation and benefits expense are described in the footnotes of the reconciliation of Adjusted EBITDAC to Net income in "Reconciliation of Adjusted EBITDAC to Net Income."

------

**Reconciliation of Adjusted General and Administrative Expense to General and Administrative Expense**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **December 31,** | **December 31,** |
| (in thousands, except percentages) | **2022** | **2021** |
| **Total Revenue** | $**435015** | $**378535** |
| **General and Administrative Expense** | $**57120** | $**41971** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expense | (1710) | (2147) |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related expense |  | (441) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-recurring expense |  | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;IPO related expenses | (228) | (2279) |
| **Adjusted General and Administrative Expense (1)** | $**55182** | $**37107** |
| **General and Administrative Expense Ratio** | **13.1%** | **11.1%** |
| **Adjusted General and Administrative Expense Ratio** | **12.7%** | **9.8%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)Adjustments made to General and administrative expense are described in the footnotes of the reconciliation of Adjusted EBITDAC to Net income in "Reconciliation of Adjusted EBITDAC to Net Income."

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
| (in thousands, except percentages) | **2022** | **2021** |
| **Total Revenue** | $**1725193** | $**1432771** |
| **General and Administrative Expense** | $**196971** | $**138955** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expense | (4477) | (4275) |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related expense | (4993) | (4727) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-recurring expense |  | (351) |
| &nbsp;&nbsp;&nbsp;&nbsp;IPO related expenses | (1545) | (3625) |
| **Adjusted General and Administrative Expense (1)** | $**185956** | $**125977** |
| **General and Administrative Expense Ratio** | **11.4%** | **9.7%** |
| **Adjusted General and Administrative Expense Ratio** | **10.8%** | **8.8%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)Adjustments made to General and administrative expense are described in the footnotes of the reconciliation of Adjusted EBITDAC to Net income in "Reconciliation of Adjusted EBITDAC to Net Income."

------

**Reconciliation of Adjusted EBITDAC to Net Income**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **December 31,** | **December 31,** |
| (in thousands, except percentages) | **2022** | **2021** |
| **Total Revenue** | $**435015** | $**378535** |
| **Net Income** | $**45782** | $**29616** |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 29367 | 19130 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 5859 | 5734 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 1787 | 1205 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 25038 | 25782 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in contingent consideration | 1279 | 535 |
| **EBITDAC** | $**109112** | $**82002** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expense (1) | 1710 | 2147 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition related long-term incentive compensation (2) | (88) | 9568 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related expense (3) |  | 1129 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization and expense related to discontinued prepaid incentives (4) | 1663 | 1768 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-operating loss (income) (5) | (1759) | (600) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation (6) | 5380 | 2380 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-recurring expense |  | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;IPO related expenses (7) | 11244 | 20557 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Income) / loss from equity method investments in related party |  | 1369 |
| **Adjusted EBITDAC** | $**127262** | $**120317** |
| **Net Income Margin (8)** | **10.5%** | **7.8%** |
| **Adjusted EBITDAC Margin** | **29.3%** | **31.8%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)Acquisition-related expense includes diligence, transaction-related, and integration costs. General and administrative expenses contributed to $1.7 million and $2.1 million of the acquisition-related expense for the three months ended December 31, 2022 and 2021, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;(2)Acquisition related long-term incentive compensation arises from long-term incentive plans associated with acquisitions.

&nbsp;&nbsp;&nbsp;&nbsp;(3)Restructuring and related expense consists of de minimis Compensation and benefits for the three months ended December 31, 2022 and $0.7 million for the three months ended December 31, 2021, and General and administrative costs including occupancy and professional services fees of $0.4 million for the three months ended December 31, 2021, related to the restructuring plan. The Compensation and benefits expense includes severance as well as employment costs related to services rendered between the notification and termination dates. See "Note 5, Restructuring" of the audited consolidated financial statements for further details. The remaining costs that preceded the restructuring plan were associated with organizational design, other severance, and non-recurring lease costs.

&nbsp;&nbsp;&nbsp;&nbsp;(4)Amortization and expense related to discontinued prepaid incentive programs – see "Note 15, Employee Benefit Plans, Prepaid and Long-Term Incentives" of the audited consolidated financial statements for further detail.

&nbsp;&nbsp;&nbsp;&nbsp;(5)For the three months ended December 31, 2022 and 2021, Other non-operating loss (income) includes a $(1.7) million and $(0.6) million, change in the TRA liability, respectively, caused by an update in our blended state tax rates.

&nbsp;&nbsp;&nbsp;&nbsp;(6)Equity-based compensation reflects non-cash equity-based expense.

&nbsp;&nbsp;&nbsp;&nbsp;(7)IPO related expenses include $0.2 million and $2.3 million of General and administrative expense associated with the preparations for Sarbanes-Oxley compliance, tax, and accounting advisory services on IPO-related structure changes for the three months ended December 31, 2022 and 2021, respectively, and compensation-related expense of $11.0 million and $18.3 million for the three months ended December 31, 2022 and 2021, respectively, primarily related to the revaluation of existing equity awards at the IPO as well as expense for new awards issued at the IPO.

&nbsp;&nbsp;&nbsp;&nbsp;(8)Net income margin is Net income as a percentage of Total revenue.

------

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
| (in thousands, except percentages) | **2022** | **2021** |
| **Total Revenue** | $**1725193** | $**1432771** |
| **Net Income** | $**163257** | $**56632** |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 104829 | 79354 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 15935 | 4932 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 5690 | 4806 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 103601 | 107877 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in contingent consideration | 442 | 2891 |
| **EBITDAC** | $**393754** | $**256492** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expense (1) | 4599 | 4275 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition related long-term incentive compensation (2) | 22093 | 38405 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related expense (3) | 5717 | 14661 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization and expense related to discontinued prepaid incentives (4) | 6738 | 7209 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-operating loss (income) (5) | 5073 | 44947 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation (6) | 23390 | 13639 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-recurring expense (7) |  | 351 |
| &nbsp;&nbsp;&nbsp;&nbsp;IPO related expenses (8) | 55636 | 79493 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Income) / loss from equity method investments in related party | 414 | 759 |
| **Adjusted EBITDAC (9)** | $**517414** | $**460231** |
| **Net Income Margin (10)** | **9.5%** | **4.0%** |
| **Adjusted EBITDAC Margin** | **30.0%** | **32.1%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)Acquisition-related expense includes diligence, transaction-related, and integration costs. Compensation and benefits expenses were $0.1 million for the year ended December 31, 2022, while General and administrative expenses contributed to $4.5 million and $4.3 million of the acquisition-related expense for the years ended December 31, 2022 and 2021, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;(2)Acquisition related long-term incentive compensation arises from long-term incentive plans associated with acquisitions.

&nbsp;&nbsp;&nbsp;&nbsp;(3)Restructuring and related expense consists of compensation and benefits of $0.7 million and $9.9 million for the years ended December 31, 2022 and 2021, respectively, and General and administrative costs including occupancy and professional services fees of $5.0 million and $4.7 million for the years ended December 31, 2022 and 2021, respectively, related to the restructuring plan. The compensation and benefits expense includes severance as well as employment costs related to services rendered between the notification and termination dates. See "Note 5, Restructuring" of the audited consolidated financial statements for further details. The remaining costs that preceded the restructuring plan were associated with organizational design, other severance, and non-recurring lease costs.

&nbsp;&nbsp;&nbsp;&nbsp;(4)Amortization and expense related to discontinued prepaid incentive programs – see "Note 15, Employee Benefit Plans, Prepaid and Long-Term Incentives" of the audited consolidated financial statements for further details.

&nbsp;&nbsp;&nbsp;&nbsp;(5)For the year ended December 31, 2022, Other non-operating loss includes a $5.6 million charge related to the change in the TRA liability caused by a change in our blended state tax rates. For the year ended December 31, 2021, Other non-operating loss includes the change in fair value of the embedded derivatives on the preferred equity. This change in fair value of $36.9 million was due to the occurrence of our IPO. The loss in 2021 also includes expense of $8.6 million associated with the extinguishment of a portion of our deferred debt issuance costs on the term debt.

&nbsp;&nbsp;&nbsp;&nbsp;(6)Equity-based compensation reflects non-cash equity-based expense.

&nbsp;&nbsp;&nbsp;&nbsp;(7)Other non-recurring expense includes one-time impacts that do not reflect the core performance of the business, including General and administrative expenses of $0.4 million for the year ended December 31, 2021, and de minimis Compensation and benefits expense for the years ended December 31, 2022 and 2021, respectively. Other non-recurring items include one-time professional services costs associated with term debt repricing, and one-time non-income tax charges and tax and accounting consultancy costs associated with potential structure changes.

&nbsp;&nbsp;&nbsp;&nbsp;(8)IPO related expenses includes $1.5 million and $3.6 million for the years ended December 31, 2022 and 2021, respectively, of General and administrative expense associated with the preparations for Sarbanes-Oxley compliance, tax and accounting advisory services on IPO-related structure changes, and Compensation-related expense of $54.1 million and $75.9 million for the years ended December 31, 2022 and 2021, respectively, related primarily to the revaluation of existing equity awards at the IPO as well as expense for new awards issued at the IPO.

------

&nbsp;&nbsp;&nbsp;&nbsp;(9)Consolidated Adjusted EBITDAC does not reflect a deduction for the Adjusted EBITDAC associated with the non-controlling interest in Ryan Re for the period of time prior to March 31, 2021 when the Company did not own 100% of Ryan Re.

&nbsp;&nbsp;&nbsp;&nbsp;(10)Net income margin is Net income as a percentage of Total revenue.

------

**Reconciliation of Adjusted Net Income to Net Income**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** |
|  | **December 31,** | **December 31,** |
| (in thousands, except percentages) | **2022** | **2021** |
| **Total Revenue** | $**435015** | $**378535** |
| **Net Income** | $**45782** | $**29616** |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 5859 | 5734 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 25038 | 25782 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred debt issuance costs (1) | 3037 | 2826 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in contingent consideration | 1279 | 535 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expense (2) | 1710 | 2147 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition related long-term incentive compensation (3) | (88) | 9568 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related expense (4) |  | 1129 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization and expense related to discontinued prepaid incentives (5) | 1663 | 1768 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-operating loss (income) (6) | (1759) | (600) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation (7) | 5380 | 2380 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-recurring expense |  | (3) |
| &nbsp;&nbsp;&nbsp;&nbsp;IPO related expenses (8) | 11244 | 20557 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Income) / loss from equity method investments in related party |  | 1369 |
| **Adjusted Income before Income Taxes** | $**99145** | $**102808** |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted tax expense (9) | (25312) | (25825) |
| **Adjusted Net Income** | $**73833** | $**76983** |
| **Net Income Margin (10)** | **10.5%** | **7.8%** |
| **Adjusted Net Income Margin** | **17.0%** | **20.3%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)Interest expense, net includes amortization of deferred debt issuance costs.

&nbsp;&nbsp;&nbsp;&nbsp;(2)Acquisition-related expense includes diligence, transaction-related, and integration costs. General and administrative expenses contributed to $1.7 million and $2.1 million of the acquisition-related expense for the three months ended December 31, 2022 and 2021, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;(3)Acquisition related long-term incentive compensation arises from long-term incentive plans associated with acquisitions.

&nbsp;&nbsp;&nbsp;&nbsp;(4)Restructuring and related expense consists of de minimis Compensation and benefits for the three months ended December 31, 2022 and $0.7 million for the three months ended December 31, 2021, and General and administrative costs including occupancy and professional services fees of $0.4 million for the three months ended December 31, 2021, related to the Restructuring Plan. The Compensation and benefits expense includes severance as well as employment costs related to services rendered between the notification and termination dates. See "Note 5, Restructuring" of the audited consolidated financial statements for further detail. The remaining costs that preceded the Restructuring Plan were associated with organizational design, other severance, and non-recurring lease costs.

&nbsp;&nbsp;&nbsp;&nbsp;(5)Amortization and expense related to discontinued prepaid incentive programs – see "Note 15, Employee Benefit Plans, Prepaid and Long-Term Incentives" of the audited consolidated financial statements for further detail.

&nbsp;&nbsp;&nbsp;&nbsp;(6)For the three months ended December 31, 2022 and 2021, Other non-operating loss (income) includes a $(1.7) million and $(0.6) million, change in the TRA liability, respectively, caused by an update in our blended state tax rates.

&nbsp;&nbsp;&nbsp;&nbsp;(7)Equity-based compensation reflects non-cash equity-based expense.

&nbsp;&nbsp;&nbsp;&nbsp;(8)IPO related expenses include $0.2 million and $2.3 million of General and administrative expense associated with the preparations for Sarbanes-Oxley compliance, tax, and accounting advisory services on IPO-related structure changes for the three months ended December 31, 2022 and 2021, respectively, and compensation-related expense of $11.0 million and $18.3 million for the three months ended December 31, 2022 and 2021, respectively, primarily related to the revaluation of existing equity awards at the IPO as well as expense for new awards issued at the IPO.

&nbsp;&nbsp;&nbsp;&nbsp;(9)The Company is subject to United States federal income taxes, in addition to state, local, and foreign taxes, with respect to its allocable share of any net taxable income of the LLC. For the three months ended December 31, 2022 this calculation of adjusted tax expense is based on a federal statutory rate of 21% and a combined state income tax rate net of federal benefits of 4.53% on 100% of adjusted income before income taxes as if the Company owned 100% of the LLC. For the three months ended December 31, 2021 this calculation of adjusted tax expense is based on a

------

federal statutory rate of 21% and a combined state income tax rate net of federal benefits of 4.12% on 100% of adjusted income before income taxes as if the Company owned 100% of the LLC.

&nbsp;&nbsp;&nbsp;&nbsp;(10)Net income margin is Net income as a percentage of Total revenue.

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
| (in thousands, except percentages) | **2022** | **2021** |
| **Total Revenue** | $**1725193** | $**1432771** |
| **Net Income** | $**163257** | $**56632** |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 15935 | 4932 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization | 103601 | 107877 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred debt issuance costs (1) | 12054 | 11372 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in contingent consideration | 442 | 2891 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related expense (2) | 4599 | 4275 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition related long-term incentive compensation (3) | 22093 | 38405 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring and related expense (4) | 5717 | 14661 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization and expense related to discontinued prepaid incentives (5) | 6738 | 7209 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-operating loss (income) (6) | 5073 | 44947 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation (7) | 23390 | 13639 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-recurring expense (8) |  | 351 |
| &nbsp;&nbsp;&nbsp;&nbsp;IPO related expenses (9) | 55636 | 79493 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Income) / loss from equity method investments in related party | 414 | 759 |
| **Adjusted Income before Income Taxes** | $**418949** | $**387443** |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted tax expense (10) | (106958) | (97326) |
| **Adjusted Net Income (11)** | $**311991** | $**290117** |
| **Net Income Margin (12)** | **9.5%** | **4.0%** |
| **Adjusted Net Income Margin** | **18.1%** | **20.2%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)Interest expense, net includes amortization of deferred debt issuance costs.

&nbsp;&nbsp;&nbsp;&nbsp;(2)Acquisition-related expense includes diligence, transaction-related, and integration costs. Compensation and benefits expenses were $0.1 million for the year ended December 31, 2022, while General and administrative expenses contributed to $4.5 million and $4.3 million of the acquisition-related expense for the years ended December 31, 2022 and 2021, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;(3)Acquisition related long-term incentive compensation arises from long-term incentive plans associated with acquisitions.

&nbsp;&nbsp;&nbsp;&nbsp;(4)Restructuring and related expense consists of compensation and benefits of $0.7 million and $9.9 million for the years ended December 31, 2022 and 2021, respectively, and General and administrative costs including occupancy and professional services fees of $5.0 million and $4.7 million for the years ended December 31, 2022 and 2021, respectively, related to the Restructuring Plan. The compensation and benefits expense includes severance as well as employment costs related to services rendered between the notification and termination dates. See "Note 5, Restructuring" of the audited consolidated financial statements for further detail. The remaining costs that preceded the Restructuring Plan were associated with organizational design, other severance, and non-recurring lease costs.

&nbsp;&nbsp;&nbsp;&nbsp;(5)Amortization and expense related to discontinued prepaid incentive programs – see "Note 15, Employee Benefit Plans, Prepaid and Long-Term Incentives" of the audited consolidated financial statements for further detail.

&nbsp;&nbsp;&nbsp;&nbsp;(6)For the year ended December 31, 2022, Other non-operating loss includes a $5.6 million charge related to the change in the TRA liability caused by a change in our blended state tax rates. For the year ended December 31, 2021, Other non-operating loss includes the change in fair value of the embedded derivatives on the Redeemable Preferred Units. This change in fair value of $36.9 million was due to the occurrence of a Realization Event in the third quarter of 2021, which is defined as a Qualified Public Offering or a Sale Transaction in the Onex Purchase Agreement. The loss in 2021 also includes expense of $8.6 million associated with the extinguishment of a portion of our deferred debt issuance costs on the term debt.

&nbsp;&nbsp;&nbsp;&nbsp;(7)Equity-based compensation reflects non-cash equity-based expense.

&nbsp;&nbsp;&nbsp;&nbsp;(8)Other non-recurring expense includes one-time impacts that do not reflect the core performance of the business, including General and administrative expenses of $0.4 million for the year ended December 31, 2021, and de minimis

------

Compensation and benefits expense for the years ended December 31, 2022 and 2021. Other non-recurring items include one-time professional services costs associated with term debt repricing, and one-time non-income tax charges and tax and accounting consultancy costs associated with potential structure changes.

&nbsp;&nbsp;&nbsp;&nbsp;(9)IPO related expenses includes $1.5 million and $3.6 million for the years ended December 31, 2022 and 2021, respectively, of General and administrative expense associated with the preparations for Sarbanes-Oxley compliance, tax and accounting advisory services on IPO-related structure changes, and Compensation-related expense of $54.1 million and $75.9 million for the years ended December 31, 2022 and 2021, respectively, related primarily to the revaluation of existing equity awards at the IPO as well as expense for new awards issued at the IPO.

&nbsp;&nbsp;&nbsp;&nbsp;(10)The Company is subject to United States federal income taxes, in addition to state, local, and foreign taxes, with respect to its allocable share of any net taxable income of the LLC. For the year ended December 31, 2022 this calculation of adjusted tax expense is based on a federal statutory rate of 21% and a combined state income tax rate net of federal benefits of 4.53% on 100% of adjusted income before income taxes as if the Company owned 100% of the LLC. For the year ended December 31, 2021 this calculation of adjusted tax expense is based on a federal statutory rate of 21% and a combined state income tax rate net of federal benefits of 4.12% on 100% of adjusted income before income taxes as if the Company owned 100% of the LLC.

&nbsp;&nbsp;&nbsp;&nbsp;(11)Consolidated Adjusted net income does not reflect a deduction for the Adjusted net income associated with the non-controlling interest in Ryan Re for the period of time prior to March 31, 2021 when the Company did not own 100% of Ryan Re or the non-controlling interest attributed to the retained ownership of the LLC.

&nbsp;&nbsp;&nbsp;&nbsp;(12)Net income (loss) margin is Net income (loss) as a percentage of Total revenue.

------

**Reconciliation of Adjusted Diluted Earnings per Share to Diluted Earnings per Share**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** | **Three Months Ended December 31, 2022** |
|  |  | **Adjustments** | **Adjustments** | **Adjustments** | **Adjustments** |  |
| (in thousands, except per share data) | **U.S. GAAP** | **Less: Net income attributed to dilutive awards and substantively vested shares (1)** | **Plus: Net income attributed to non-controlling interests (2)** | **Plus: Adjustments to Adjusted net income <br>(3)** | **Plus: Dilutive impact of unvested equity awards <br>(4)** | **Adjusted diluted earnings per share** |
| **Numerator:** |  |  |  |  |  |  |
| Net income attributable to Class A<br> common shareholders- diluted | $38722 | $(20827) | $27887 | $28051 | $— | $73833 |
| **Denominator:** |  |  |  |  |  |  |
| Weighted-average shares of Class A<br> common stock outstanding- diluted | 267771 |  |  |  | 2871 | 270642 |
| **Net income per share of Class A<br> common stock- diluted** | $**0.14** | $**(0.08)** | $**0.10** | $**0.10** | $**(0.00)** | $**0.27** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)Adjustment removes the impact of Net income attributed to dilutive awards and substantively vested RSUs to arrive at Net income attributable to Ryan Specialty Holdings, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;(2)For comparability purposes, this calculation incorporates the Net income that would be outstanding if all LLC Common Units (together with shares of Class B common stock) were exchanged for shares of Class A common stock. 143,960 weighted average outstanding LLC Common Units were considered dilutive for the three months ended December 31, 2022 and included in the 267,771 Weighted-average shares outstanding within Diluted earnings (loss) per share.

&nbsp;&nbsp;&nbsp;&nbsp;(3)Adjustments to Adjusted net income are described in the footnotes of the reconciliation of Adjusted net income to Net income in "Adjusted Net Income and Adjusted Net Income Margin".

&nbsp;&nbsp;&nbsp;&nbsp;(4)For comparability purposes and to be consistent with the treatment of the adjustments to arrive at Adjusted net income, the dilutive effect of unvested equity awards is calculated using the treasury stock method as if the weighted average unrecognized cost associated with the awards was $0 over the period, less any unvested equity awards determined to be dilutive within the Diluted earnings per share calculation.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** | **Three Months Ended December 31, 2021** |
|  |  | **Adjustments** | **Adjustments** | **Adjustments** | **Adjustments** |  |
| (in thousands, except per share data) | **U.S. GAAP** | **Less: Net income attributed to dilutive awards and substantively vested shares (1)** | **Plus: Impact of all LLC Common Units exchanged for Class A shares (2)** | **Plus: Adjustments to Adjusted net income <br>(3)** | **Plus: Dilutive impact of unvested equity awards <br>(4)** | **Adjusted diluted earnings per share** |
| **Numerator:** |  |  |  |  |  |  |
| Net income (loss) attributable to Class A<br> common shareholders- diluted | $10534 | $(483) | $19565 | $47367 | $— | $76983 |
| **Denominator:** |  |  |  |  |  |  |
| Weighted-average shares of Class A<br> common stock outstanding- diluted | 113531 |  | 143153 |  | 11852 | 268536 |
| **Net income (loss) per share of Class A<br> common stock- diluted** | $**0.09** | $**—** | $**0.02** | $**0.19** | $**(0.01)** | $**0.29** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)Adjustment removes the impact of Net income attributed to dilutive awards and substantively vested RSUs to arrive at Net income attributable to Ryan Specialty Holdings, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;(2)For comparability purposes, this calculation incorporates the net income (loss) and weighted average shares of Class A common stock that would be outstanding if all LLC Common Units (together with shares of Class B common stock)

------

were exchanged for shares of Class A common stock and the non-controlling interest in Ryan Re for the period of time prior to March 31, 2021 when the Company did not own 100% of the business.

&nbsp;&nbsp;&nbsp;&nbsp;(3)Adjustments to Adjusted Net Income are described in the footnotes of the reconciliation of Adjusted Net Income to Net Income in "Adjusted Net Income and Adjusted Net Income Margin".

&nbsp;&nbsp;&nbsp;&nbsp;(4)For comparability purposes and to be consistent with the treatment of the adjustments to arrive at Adjusted Net Income, the dilutive effect of unvested equity awards is calculated using the treasury stock method as if the weighted average unrecognized cost associated with the awards was $0 over the period, less any unvested equity awards determined to be dilutive within the Diluted loss per share calculation.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** | **Year Ended December 31, 2022** |
|  |  | **Adjustments** | **Adjustments** | **Adjustments** | **Adjustments** |  |
| (in thousands, except per share data) | **U.S. GAAP** | **Less: Net income attributed to dilutive awards and substantively vested shares (1)** | **Plus: Net income attributed to non-controlling interests (2)** | **Plus: Adjustments to Adjusted net income <br>(3)** | **Plus: Dilutive impact of unvested equity awards <br>(4)** | **Adjusted diluted earnings per share** |
| **Numerator:** |  |  |  |  |  |  |
| Net income attributable to Class A<br> common shareholders- diluted | $137370 | $(76318) | $102205 | $148734 | $— | $311991 |
| **Denominator:** |  |  |  |  |  |  |
| Weighted-average shares of Class A<br> common stock outstanding- diluted | 265750 |  |  |  | 4731 | 270481 |
| **Net income per share of Class A<br> common stock- diluted** | $**0.52** | $**(0.29)** | $**0.38** | $**0.56** | $**(0.02)** | $**1.15** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)Adjustment removes the impact of Net income attributed to dilutive awards and substantively vested RSUs to arrive at Net income attributable to Ryan Specialty Holdings, Inc. See "Note 13, Earnings (Loss) Per Share" of the audited consolidated financial statements in the Annual Report.

&nbsp;&nbsp;&nbsp;&nbsp;(2)For comparability purposes, this calculation incorporates the Net income that would be outstanding if all LLC Common Units (together with shares of Class B common stock) were exchanged for shares of Class A common stock. 143,992 weighted average outstanding LLC Common Units were considered dilutive for the year ended December 31, 2022 and included in the 265,750 Weighted-average shares outstanding within Diluted earnings (loss) per share. See "Note 13, Earnings (Loss) Per Share" of the audited consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;(3)Adjustments to Adjusted net income are described in the footnotes of the reconciliation of Adjusted net income to Net income in "Adjusted Net Income and Adjusted Net Income Margin".

&nbsp;&nbsp;&nbsp;&nbsp;(4)For comparability purposes and to be consistent with the treatment of the adjustments to arrive at Adjusted net income, the dilutive effect of unvested equity awards is calculated using the treasury stock method as if the weighted average unrecognized cost associated with the awards was $0 over the period, less any unvested equity awards determined to be dilutive within the Diluted earnings per share calculation disclosed in "Note 13, Earnings (Loss) Per Share" of the audited consolidated financial statements.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** | **Year Ended December 31, 2021** |
|  |  | **Adjustments** | **Adjustments** | **Adjustments** | **Adjustments** |  |
| (in thousands, except per share data) | **U.S. GAAP** | **Plus: Net income (loss) attributable to the LLC before the Organizational Transactions** | **Plus: Impact of all LLC Common Units exchanged for Class A shares (1)** | **Plus: Adjustments to Adjusted net income <br>(2)** | **Plus: Dilutive impact of unvested equity awards <br>(3)** | **Adjusted diluted earnings per share** |
| **Numerator:** |  |  |  |  |  |  |
| Net income (loss) attributable to Class A<br> common shareholders- diluted | $(7064) | $72937 | $(9241) | $233485 | $— | $290117 |
| **Denominator:** |  |  |  |  |  |  |
| Weighted-average shares of Class A<br> common stock outstanding- diluted | 105730 |  | 142968 |  | 19313 | 268011 |
| **Net income (loss) per share of Class A<br> common stock- diluted** | $**(0.07)** | $**0.69** | $**(0.40)** | $**0.94** | $**(0.08)** | $**1.08** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1)For comparability purposes, this calculation incorporates the net income (loss) and weighted average shares of Class A common stock that would be outstanding if all LLC Common Units (together with shares of Class B common stock) were exchanged for shares of Class A common stock and the non-controlling interest in Ryan Re for the period of time prior to March 31, 2021 when the Company did not own 100% of the business.

&nbsp;&nbsp;&nbsp;&nbsp;(2)Adjustments to Adjusted net income are described in the footnotes of the reconciliation of Adjusted net income to Net Income in "Adjusted Net Income and Adjusted Net Income Margin".

&nbsp;&nbsp;&nbsp;&nbsp;(3)For comparability purposes and to be consistent with the treatment of the adjustments to arrive at Adjusted Net Income, the dilutive effect of unvested equity awards is calculated using the treasury stock method as if the weighted average unrecognized cost associated with the awards was $0 over the period, less any unvested equity awards determined to be dilutive within the Diluted Loss Per Share calculation disclosed in "Note 13, Earnings (Loss) Per Share" of the audited consolidated financial statements.

------